Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda save search
Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis
Published: 2022-02-16 (Crawled : 15:00) - biospace.com/
ACAD | News | $17.08 -0.64% -0.64% 990K
|
Health Technology
|
| O: -0.33%
H: 2.28%
C: 1.14%
nuplazid new drug alzheimer fda als application drug disease submission alzheimer’s alzheimer's disease resubmission alzheimer's
Tandem Diabetes Care Announces FDA Clearance for the t:slim X2 Insulin Pump to Bolus Using the t:connect Mobile App
Published: 2022-02-16 (Crawled : 14:00) - biospace.com/
TNDM | $30.92 -2.61% -2.68% 1.1M
|
Health Technology
|
| O: 1.06%
H: 1.53%
C: -1.55%
fda clearance mobile diabetes fda clearance mobile app insulin
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
Published: 2022-02-16 (Crawled : 04:00) - globenewswire.com
ATXI | $0.1311 -2.96% -3.05% 290K
|
Health Technology
|
| O: -47.54%
H: 21.88%
C: -2.19%
fda therapeutics
U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer
Published: 2022-02-15 (Crawled : 23:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.42%
H: 5.52%
C: 4.35%
krasg12 new drug treatment fda application drug therapeutics cel food lung cancer cancer fda acceptance
Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
Published: 2022-02-15 (Crawled : 23:00) - biospace.com/
CELU F | $3.17 -4.23% -4.42% 42K
|
|
| O: 4.73%
H: 5.21%
C: 3.47%
cynk-101 treatment fda drug drug designation cel orphan drug positive therapy cancer designation her2- her2
Avenue Therapeutics Stock Trading Halted TodayFDA Advisory Committee to review IV tramadol New Drug Application
Published: 2022-02-15 (Crawled : 15:30) - biospace.com/
ATXI | $0.1311 -2.96% -3.05% 290K
|
Health Technology
| Email alert
Add to watchlist
new drug day fda application drug therapeutics oda
Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901
Published: 2022-02-15 (Crawled : 15:30) - biospace.com/
LEGN | $47.16 -3.42% -3.54% 820K
|
Health Technology
|
| O: -4.15%
H: 6.75%
C: 6.65%
lb1901 clinical hold fda trial phase 1 biotech iot phase 2 phase 3
Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
Published: 2022-02-15 (Crawled : 15:30) - biospace.com/
CTXR | $0.8 -1.99% -2.02% 6.3M
|
Health Technology
|
| O: 0.65%
H: 7.1%
C: 5.16%
treatment fda phase 2 als hemorrhoids application phase 2b fda acceptance
Ambrx Biopharma Inc. Announces Submission of IND Application for ARX305 with the U.S. FDA
Published: 2022-02-15 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: -0.98%
H: 5.96%
C: 2.48%
arx305 fda biopharma application submission
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
Published: 2022-02-14 (Crawled : 15:30) - biospace.com/
PMCB | $2.215 4.48% 4.29% 5.9K
|
Manufacturing
|
| O: -2.31%
H: 1.9%
C: -3.79%
new drug fda application drug biotech iot
Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH
Published: 2022-02-14 (Crawled : 14:30) - biospace.com/
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: 1.14%
H: 7.34%
C: -5.65%
axa1125 fast track designation fda fast track therapeutics cel fda fast track nash designation
Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza
Published: 2022-02-14 (Crawled : 13:30) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.0%
H: 0.16%
C: -1.26%
CDTX | $0.7201 -0.29% -0.29% 270K
|
Health Technology
|
| O: 0.0%
H: 2.6%
C: -0.46%
cd388 new drug treatment fda application drug therapeutics fda acceptance influenza
Global Immunoassay Market Report 2022: FDA Grants Breakthrough Device to Multiplex Immunoassay
Published: 2022-02-14 (Crawled : 13:00) - prnewswire.com
TMO | News | $541.52 -1.05% 0.61% 2.1M
|
Health Technology
|
| O: -2.67%
H: 0.75%
C: -0.59%
BIO | $281.02 -3.38% -0.36% 370K
|
Health Technology
|
| O: -1.81%
H: 2.28%
C: -0.41%
BDX | $233.15 0.41% 0.15% 890K
|
Health Technology
|
| O: -0.63%
H: 0.53%
C: -0.07%
fda device report grant granted
ASCENSIA DIABETES CARE ANNOUNCES FDA APPROVAL OF THE EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM FOR USE FOR UP TO 6 MONTHS
Published: 2022-02-14 (Crawled : 12:30) - prnewswire.com
SENS | $0.416 3.43% 0.7% 2.2M
|
Electronic Technology
|
| O: -28.66%
H: 2.62%
C: -7.86%
fda fda approval approval system diabetes eversense
Motus GI Receives FDA Clearance to Market the Pure-Vu® EVS System
Published: 2022-02-14 (Crawled : 12:30) - biospace.com/
MOTS | $0.1735 -46.17% 1.4M
|
Health Technology
|
| O: 39.29%
H: 9.8%
C: -25.64%
fda clearance system fda clearance
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months; Provides 2022 Business Outlook
Published: 2022-02-11 (Crawled : 15:00) - biospace.com/
SENS | $0.416 3.43% 0.7% 2.2M
|
Electronic Technology
|
| O: -12.05%
H: 0.0%
C: 0.0%
eversense fda ces fda approval approval system
Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab
Published: 2022-02-11 (Crawled : 14:30) - biospace.com/
YMAB | $14.97 -0.93% -0.94% 410K
|
Health Technology
|
| O: 3.82%
H: 0.0%
C: 0.0%
fda
FDA Advisory Committee Votes to Recommend Additional Data for Sintilimab Submission
Published: 2022-02-11 (Crawled : 03:00) - prnewswire.com
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
fda submission
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.